^
Association details:
| Biomarker: | MGMT expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) + temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3265 / 6 - Temozolomide combined with ipilimumab + nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells
Published date:
03/15/2023
Excerpt:
Our results indicate that TMZ sensitizes MSS, MGMT-expressing CRC cells to ipilimumab + nivolumab ICI.
Source:
Title:
Temozolomide combined with ipilimumab plus nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells
Published date:
01/15/2023
Excerpt:
A similar experiment was conducted with the MGMT-expressing, MSI CRC cell line HCT116 treated with TMZ, and a similar result was observed as far as a lack of T cell killing enhancement with TMZ alone (Figure 5). Together, these results suggest that TMZ + ICI significantly enhances TALL-104-mediated killing of MSS, MGMT-expressing CRC cell lines, but each treatment alone had no effect....Our results indicate that TMZ sensitizes MSS, MGMT-expressing CRC cells to ipilimumab + nivolumab ICI.
